8th Sep 2014 08:24
LONDON (Alliance News) - Summit Corp PLC said Monday it is presenting data from a series of in-vivo and in-vitro efficacy studies of its SMT19969 compound for C. difficile infection that indicates it continues to show superiority over the current standard of care, vancomycin.
The study data will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington DC.
It shows that in comparison to vancomycin, SMT19969 provides increased survival rates and prevention of recurrent disease in vivo, superior C. difficile killing, as well as reduced toxin B production.
C. difficile bacteria infects the colon, causing serious illness, and is typically contracted by patients being treated with antibiotics which disrupt the normal gut flora.
"These results further illustrate that SMT19969 has potential to be a new and differentiated antibiotic for the treatment of initial CDI infection and for the prevention of recurrent disease, the key clinical issue," said Chief Executive Officer Glyn Edwards in a statement.
Shares in Summit Corp were trading up 0.6% at 174.00 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L